ERBB2 and breast carcinoma: In line with previous studies, we found that pre-NAT 89Zr-trastuzumab PET/CT allows the detection of HER2-positive breast cancer lesions, with a median SUVmax, SUVR and TBR of 5.55, 16.65 and 1.52, respectively [39].